PERPHENAZINE FENDIZOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H26ClN3OS.C20H14O4
Molecular Weight	722.291
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=C(C=CC=C1)C(=O)C2=CC=C(O)C(=C2)C3=CC=CC=C3.OCCN4CCN(CCCN5C6=CC=CC=C6SC7=C5C=C(Cl)C=C7)CC4

InChI

InChIKey=SPGWGYWYOAUBIB-UHFFFAOYSA-N

InChI=1S/C21H26ClN3OS.C20H14O4/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26;21-18-11-10-14(12-17(18)13-6-2-1-3-7-13)19(22)15-8-4-5-9-16(15)20(23)24/h1-2,4-7,16,26H,3,8-15H2;1-12,21H,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C20H14O4
Molecular Weight	318.3228
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C21H26ClN3OS
Molecular Weight	403.969
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=39012 | http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_1172004B1030_2_11

Perphenazine fendizoate is a salt of a typical antipsychotic drug perphenazine and fendizoic acid. Perhpenazien fendizoate is approved in Japan for the treatment of schizophrenia, preoperative and postoperative nausea and vomiting, and Meniere's disease (dizziness, ear ringing).

Approval Year

PubMed

Title	Date	PubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787
Side-effects of phenothiazines.	1967 Apr 1	6021008
Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients.	1967 Mar-Apr	5336562
Phenothiazines and diabetes in hospitalized women.	1968 Jan	5634402
Perphenazine dystonia presenting as recurrent dislocation of the jaw.	1969 Jan	5765799
Iatrogenic epilepsy due to antidepressant drugs.	1969 Oct 11	5823053
[Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)].	1975 Dec	1233531
Drug-induced dystonia.	1975 May	1119613
Tetany, tetanus or drug reaction? A case report.	1976 Jul	1016648
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.	1977 Mar 12	65671
[Acute dystonia in children. 2 cases caused by perphenazine (Trilafon)].	1978 Mar 10	635871
Prolactin and the small intestine. Effect of hyperprolactinaemia on mucosal structure in the rat.	1981 Jul	7262630
Tricyclic antidepressants and alcoholic blackouts.	1981 Jun	7229637
L-tryptophan in drug-induced movement disorders with insomnia.	1986 May 8	3702925
Neuroleptic malignant syndrome during perphenazine treatment.	1987 Mar	3588517
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.	1990 Aug	2199431
D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.	1992	1365866
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.	1993 Dec	7508675
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.	1995 Jul	7598243
BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.	1996	9013402
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.	1998 Oct	9766782
Acquired aplastic anemia secondary to perphenazine.	1999 Autumn	10495369
Perphenazine-induced hiccups.	1999 Mar	10333169
[Diabetes mellitus after treatment with clozapine].	2000 Feb 26	10719549
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Role of adenosine in drug-induced catatonia in mice.	2002 Aug	12597016
Drug-induced toxic myocarditis.	2003	12638679
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.	2004 Apr 27	15109398
An unexpected increase of troponin I after perphenazine depot injection.	2004 Feb	14742781
Induction of the rabbit syndrome following coadministration of paroxetine, perphenazine, and amitriptyline.	2004 Nov-Dec	15613935
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.	2005 May	15821958
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006 Jun	16856516
Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.	2008	18032895
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008 Dec	18493746
[Consumption of inappropriate psychotropic drugs in residential homes for the elderly: comparative study between 2001 and 2006].	2008 Mar-Apr	18783709
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.	2010 Apr 11	20097249
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.	2010 Dec	21158687
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.	2010 Feb 23	20142494
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.	2014 Jun	24709263

Patents

Sample Use Guides

In Vivo Use Guide

Schizophrenia: In general, for adults, the dose is 0.6 to 4.8 g (6 to 48 mg as perphenazine) daily in several divided oral doses.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:07:11 GMT 2023` Edited by `admin` on `Sat Dec 16 11:07:11 GMT 2023`
Record UNII	YU5QUY724S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERPHENAZINE FENDIZOATE

Common Name

English

Perphenazine fendizoate [WHO-DD]

Common Name

English

BENZOIC ACID, 2-((6-HYDROXY(1,1'-BIPHENYL)-3-YL)CARBONYL)-, COMPD. WITH 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL (1:1)

Systematic Name

English

PERPHENAZINE FENDIZOATE [JAN]

Common Name

English

BENZOIC ACID, O-((6-HYDROXY-3-BIPHENYLYL)CARBONYL)-, COMPD. WITH 4-(3-(2-CHLOROPHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL

Systematic Name

English

Code System Code Type Description

EVMPD

SUB194304